Previous Statements by FOLD
» Amicus Therapeutics CEO Discusses Q3 2010 Results - Earnings Call Transcript
» Amicus Therapeutics Agreement with GSK - Call Transcript
» Amicus Therapeutics, Inc. Q2 2010 Earnings Call Transcript
Absent specific policy details, Trump's speech leaves investors guessing about his real plans for the FDA and the drug approval process. He has not yet named an FDA commissioner.
Amicus Therapeutics, Nantkwest and Organovo are among the premarket biotech movers on Tuesday.